Antibodies in clinical trials for Solid Tumors

Solid tumors contain abnormal and heterotypic cells that communicate through tight and gap junctions. In contrast with liquid tumors, as the cells multiply, they form a “mass” called a solid tumor and usually do not contain pockets of fluid, pus, air, or other substances. Solid tumors can be either non-cancerous (benign), pre-malignant (cells that have the potential to become malignant), or malignant (cancerous).

Solid tumors represent approximatively 90% of adult human cancers. They can develop in many parts of the human body, including the breast, lung, prostate, colon, melanoma, bladder, and kidney.

Examples of localized solid tumors:

  • Carcinomas
  • Sarcomas
  • Lymphomas
  • Carcinosarcomas

In early stages of clinical trials is “solid tumours” is often used as a catch-all when testing new drugs and combinations so there are no antibodies approved for this large demographic.

Antibodies that are in clinical trials for the treatment of solid tumors are:

    • AB154
    • Aprutumab
    • ASP8374
    • BGB-A1217
    • BI-754111
    • BMS-986207
    • Codrituzumab
    • COM701
    • COM902
    • Dostarlimab
    • Eigliimab
    • EOS884448
    • Lemzoparlimab
    • MK-1308
    • Naptumomab
    • Onvatilimab
    • Selicrelumab
    • SRF231
    • Sym-022
    • Tebotelimab
    • Tinurilimab
    • TSR-033
    • Utomilumab
    • Vibostolimab
    • Sym023
    • LY3321367
    • BMS986258
    • JNJ-61610588
    • HMBD-002
    • MGD009

Antibodies that are in clinical trials for combined treatment of non-small cell lung cancer are:

    • AB154 and Zimberelimab
    • ASP8374 and Pembrolizumab
    • BGB-A1217 and Tislelizumab
    • BI-754111 and BI-754091
    • BMS-986207 and Nivolumab
    • BMS-986207 and Nivolumab and Ipilimumab
    • Eigliimab and Nivolumab
    • MK-1308 and Pembrolizumab
    • Selicrelumab and Atezolizumab
    • TSR-033 and dostarlimab or bevacizumab
    • Utomilumab and mogamulizumab
    • Vibostolimab and Pembrolizumab
    • Zimberelimab and domvanalimab
    • SHR1702 and Camrelizumab
    • LY3321367 and LY3300054
    • BMS986258 and Nivolumab
    • HMBD-002 and Pembrolizumab
    • MGD009 and Retifanlimab

Click here to see the raw data and add any missing antibody drugs. If you want to manipulate the data please copy the spreadsheet first.

Leave a Reply

Your email address will not be published. Required fields are marked *